Huadong Medicine subsidiary gains psoriasis drug trial approval
Hangzhou Sino-America Huadong Pharmaceutical received approval from China's National Medical Products Administration for Phase III clinical trials of MC2-01 cream on July 25, 2025.
The topical treatment targets mild to moderate plaque psoriasis on the body and scalp. MC2-01 combines calcipotriol and betamethasone using MC2 Therapeutics' PAD technology.
The drug gained FDA approval in 2020 and European approval in 2021. Sino-America Huadong holds exclusive rights for Greater China. Huadong Medicine will proceed with clinical development and registration in China.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Huadong Medicine publishes news
Free account required • Unsubscribe anytime